311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
0 activities
B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing
1 activities
B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing
Dapsone in Relapsed/Refractory Adult and Pediatric ITP- a Longitudinal Panel Data Analysis Demonstrates Efficacy, Safety, and Dose Dependent Response Rate Mediated through Drop in Hemoglobin
1 activities
Dapsone in Relapsed/Refractory Adult and Pediatric ITP- a Longitudinal Panel Data Analysis Demonstrates Efficacy, Safety, and Dose Dependent Response Rate Mediated through Drop in Hemoglobin
Dexamethasone Versus Prednisolone in Adults with Newly Diagnosed Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
1 activities
Dexamethasone Versus Prednisolone in Adults with Newly Diagnosed Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study
1 activities
Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses
Evans Syndrome in Adults: Demographics, Associations, and Outcomes in a Nationwide Inpatient Sample Study
1 activities
Evans Syndrome in Adults: Demographics, Associations, and Outcomes in a Nationwide Inpatient Sample Study
Genetic Associations and Platelet Count Trajectories in Gestational Thrombocytopenia and Immune Thrombocytopenia during Pregnancy
1 activities
Genetic Associations and Platelet Count Trajectories in Gestational Thrombocytopenia and Immune Thrombocytopenia during Pregnancy
Identifying Gut Microbiota and Immune Host Factors Associated with Bleeding Risk in Children with Immune Thrombocytopenic Purpura
1 activities
Identifying Gut Microbiota and Immune Host Factors Associated with Bleeding Risk in Children with Immune Thrombocytopenic Purpura
Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study
1 activities
Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study
Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
1 activities
Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
Patients with Immune Thrombocytopenia Have Higher Proportion of Ultra Large VWF Multimers and Lower ADAMTS13 Activity Than Healthy Controls
1 activities
Patients with Immune Thrombocytopenia Have Higher Proportion of Ultra Large VWF Multimers and Lower ADAMTS13 Activity Than Healthy Controls
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-Fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-Mediated Diseases
1 activities
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-Fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-Mediated Diseases
Predictors of Response to Emergent Therapies in Pediatric Immune Thrombocytopenia
1 activities
Predictors of Response to Emergent Therapies in Pediatric Immune Thrombocytopenia
Protein and Gene Levels of DNAJC21 and RNF5 Proven to be Novel Drug Targets for Immune Thrombocytopenia: Insights from Mendelian Randomization-Based Post-GWAS Research
1 activities
Protein and Gene Levels of DNAJC21 and RNF5 Proven to be Novel Drug Targets for Immune Thrombocytopenia: Insights from Mendelian Randomization-Based Post-GWAS Research
Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim
1 activities
Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim
Simplifying Eligibility Criteria for Clinical Trials in Immune Thrombocytopenia Using the Platelet Count Variability Index
1 activities
Simplifying Eligibility Criteria for Clinical Trials in Immune Thrombocytopenia Using the Platelet Count Variability Index
The ‘Stop TPO-Receptor Agonist in ITP Patients’ (STIP) Study: Clinical and Immune Modulatory Effects of Romiplostim Tapering
1 activities
The ‘Stop TPO-Receptor Agonist in ITP Patients’ (STIP) Study: Clinical and Immune Modulatory Effects of Romiplostim Tapering